PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

In 2013, Herceptin was the market leader, taking 92% of the Japanese market. This is due to the fact that it is the most established agent in this disease and is used in all settings, although over half of all Herceptin use is in the adjuvant setting.

Full Report Details at
- http://www.fastmr.com/prod/901477_pharmapoint_her2positive_breast_cancer_japan_drug.aspx?afid=301

Scope

* An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
* Annualized the Japan HER2-Positive Breast Cancer market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
* Investigation of current and future market competition for HER2-Positive Breast Cancer.
* Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
* Competitor assessment including device approval analysis and device sales forecasts.
* Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
* Analysis of unmet needs within the market and opportunities for future players.
* Technology trends evaluation to assess strength of pipeline.
* An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
* Company profiles including business description, financial overview and SWOT analysis.
* Coverage of key market players.
* Strategic assessment of the HER2-Positive Breast Cancer sector through market impact analysis, future market scenario and company analysis.
* Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to Get this Report

* Understand the trends shaping and driving the Japan HER2-Positive Breast Cancer market.
* Realize device preferences of physicians who have performed the tests already.
* Access market sizing, forecasts and quantified growth opportunities in the Japan HER2-Positive Breast Cancer market through 2018.
* Quantify candidate patient populations to better design product pricing & launch plans.
* Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
* Perform benchmarking analysis of growth opportunities against currently marketed products.
* Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023
- Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023
- Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023